<DOC>
	<DOCNO>NCT01383109</DOCNO>
	<brief_summary>The combination pyronaridine artesunate antimalarial therapy development . This Mass Balance study intend determine rate extent excretion total radioactivity urine faeces follow administration single oral micro-dose 14C-pyronaridine human .</brief_summary>
	<brief_title>Human Mass Balance Study Pyronaridine</brief_title>
	<detailed_description>This study monocenter , open-label , non-placebo-controlled , single-group , single-dose study . Six subject receive single dose Pyronaridine 720 mg orally administer together 14C-Pyronaridine ( approx . 100 µg , 800 nCi ( 29600 Bq ) . Safety measurement ( 12-lead ECG , vital sign , blood chemistry haematology ) adverse event monitor throughout study . Subjects come clinic even dose Pyronaridine . After drug intake day 1 , subject regular in-house period specimen collection 87 day drug administration Blood , faeces urine collect hospitalisation period . Samples analyze radioactivity Accelerator Mass Spectrometry ( AMS ) .</detailed_description>
	<mesh_term>Pyronaridine</mesh_term>
	<criteria>1 . Male subject age 40 55 year body weight 60 90 kg body mass index calculate use Quetelet 's Index weight ( kg ) /height2 ( m2 ) 18.5 30.0 2 . Signed date write informed consent form ( ICF ) undergo study related activity , include discontinuation prohibit medication 3 . Medically normal subject significant abnormal finding screen physical examination evaluate investigator 4 . Strictly normal value ALT , AST bilirubin normal abnormal clinically insignificant result ( agreed Investigator Sponsor case case evaluation ) blood urine laboratory parameter screen 5 . All sexually active male subject partner willing undergo contraception follow : All male subject , include sterilise ( i.e. , vasectomy ) , use condom . Their female partner must also use least 1 medically acceptable form contraceptive list . Male subject must donate sperm unprotected sex study 87 day take dose investigational product . Medically acceptable contraceptive study : Condoms addition : Intrauterine device Hormonal contraceptive ( oral , depot , patch , injectable , vaginal ring ) Diaphragms spermicidal cream gel Cervical cap spermicidal cream gel Spermicidal foam 6 . The ability understand requirement study willingness comply study procedures 1 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , acute QTc interval great equal 450 mseconds ) , respiratory ( include active tuberculosis ) , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric clinical abnormality 2 . Known history hypersensitivity , allergic adverse reaction Pyronaridine 3 . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) 4 . Seropositive HIV antibody 5 . Previous participation clinical study Pyramax 6 . Presence recent history ( last two year ) tobacco abuse ( ≥10 cigarettes/day ) 7 . Known suspected alcohol abuse illicit drug use last 10 year study start positive finding urine drug screen 8 . Intake grapefruit grapefruit juice alcoholic beverage caffeinecontaining food beverage , coffee , tea , chocolate , cola , 48 hour study drug administration 9 . Use overthecounter ( OTC ) medication , include vitamin , analgesic , antacid , 1 week study start 10 . Use prescription medication 14 day study start require chronic use prescription medication 11 . Use enzymealtering agent ( e.g. , barbiturate , phenothiazine , cimetidine , etc . ) within 30 day 5 half life , whichever longer , study start 12 . Plasma donation 1 month study start 13 . Blood donation 450 mL last 3 month study start 14 . Participation clinical trial previous month investigational drug commercially available drug test 15 . Exposure artificial ionizing radiation last 12 month ( e.g. , xray investigation , isotope study )</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Mass Balance</keyword>
	<keyword>Accelerated Mass Spectrometry ( AMS )</keyword>
	<keyword>microdose</keyword>
	<keyword>Focus study : ADME</keyword>
</DOC>